Our History

View all milestones

• 1948

  Giorgio Kropf, together with a pharmacist friend, founded Farmimport in Trieste — the original core from which Eurospital would later emerge. This marked a historic milestone: the company imports streptomycin from the American company Merck, becoming the first antibiotic available in Italy to treat tuberculosis.

• 1950

  Giorgio Kropf collaborates with pharma industry leader Don Baxter to establish the first Blood Bank in Trieste—Italy’s second after Turin. The infusion solutions line is imported from Baxter, and becoming one of the company’s flagship products.

• 1952

  Production laboratories are established, and an agreement is reached with the London-based Allen & Hanburys to manufacture infusion solutions and other licensed products in Trieste on behalf of both pharma companies.

• 1955

  Licensed production of Haliborange begins — an effective multivitamin and one of the highly regarded and consistently best-performing pharmaceutical products in Eurospital portfolio.

• 1958

  The BAXTER line of intravenous solutions and blood-related equipment is expanded with a range of blood refrigerators and medical-hospital devices. At the same time, Eurospital begins marketing Dequadin Tincture 28 ml and 10 ml, a medication for the treatment of oral cavity inflammations.

• 1962

  Hella Kropf, a great innovator and lifelong partner of Giorgio Kropf — who prematurely passed away — succeeds her husband, becoming one of the first women in Italy to lead a company.

• 1967

  The company makes a permanent move to its new — and still current — headquarters in Via Flavia.

• 1968

  Stylex, the first disposable syringe, is produced and marketed — a major step forward in the fight against hospital-acquired infections.

• 1970

  Significant production and commercial development, the workforce doubles in size.

• 1971

  Hella Kropf, as President, founds the Tre Venezie Delegation of A.I.D.D.A. (Italian Association of Women Entrepreneurs and Company Executives), affiliated with F.C.E. (Les Femmes Chefs d’Entreprises Mondiales).

• 1979

  Michele Kropf, son of Giorgio and Hella, joins the company, marking the beginning of a new chapter. Eurospital strengthens its position in the Pharmaceutical and Hospital sectors.

• 1984

  The company name changes to Eurospital Pharma.

• 1986

  The Research & Development department is established becoming a key driver in the diagnostics field, with the goal of launching innovative Eurospital-branded products in Italy and abroad. On 20/11/1986, Eurospital releases the first in a long series of diagnostic kits, fully developed and produced in-house.

• 1988

  Michele Kropf, the founder’s son, takes over the company leadership and reorganizes the business in three divisions: Pharmacy, Diagnostics and Hospital.

• 1989

  In collaboration with Burlo Garofolo and the Universities of Naples and Trieste, Eurospital develops and produces the αGliatest IgA test — the first innovative in-vitro test for detecting antibodies to gluten, responsible for the onset of celiac disease.

• 1990

  The Sterilens line is launched — the first range of contact lens solutions available in pharmacies — and Eurospital acquires brands such as Eurospital Infusion Solutions, Haliborange, Dequadin, Torch, and NonAd Garze. Licensed The Hospital Division develops Euroset, the first dual-scale flow regulator for regulated drugs delivery. The device is adopted by hospitals and healthcare centers.

• 1995

  First Italian company to certify its Quality System for the production of in vitro diagnostic devices in accordance with ISO 9001:1994 standards.

• 1997

  Eurospital acquires the exclusive worldwide license for the use of tissue transglutaminase as a specific marker for the celiac disease diagnosis, enabling the development of the innovative Eu-tTG IgA test

• 2000

  Eurospital’s laboratories develop Calprest, an in vitro test to detect fecal calprotectin concentration. In just fifteen years, it becomes an international benchmark for the non-invasive detection of intestinal inflammation.

• 2008

  Eurospital’s twenty-year commitment to study and diagnosis of celiac disease, gives rise to Piaceri Mediterranei, a food brand specifically designed for people with celiac disease.

• 2013

  Leadership at Eurospital now includes the third generation: Massimiliano and Giulia Kropf, children of Michele and grandchildren of founder Giorgio.

• 2017

  First company to receive FDA certification for the calprotectin test used to diagnosi Inflammatory Bowel Disease (IBD). Eurospital becomes the first company in Italy to obtain the TÜV America certification meeting the requirements of the MDSAP program for the United States and Canada.

• 2018

  Eurospital celebrates its 70th anniversary.
  Watch the video on Youtube

• 2020-21

  Ongoing commitment from Eurospital in supporting Italian laboratories and pharmacies in the fight against Sars-CoV-2, through innovative and high-quality products.

• 2022

  Eurospital is among the first Italian companies to receive the IVDR Certificate for in vitro diagnostic medical devices by the TÜV SÜD, one of the world’s leading providers of medical devices' certification and approval.

• 2023

  Celebration of 75th Anniversary and voluntary publication of the first Sustainability Report

• 2024

  The new Special Nutrition Area is established with the launch of Apromé, a product line of low-protein food.